HOWEVER, DESPITE THE POTENTIAL BENEFITS, SOME PATIENTS STILL FEEL EMBARRASSED BY THEIR SKIN. MANY WILL CHOOSE TO COVER UP WITH MORE CLOTHING OR AVOID SOCIAL SITUATIONS ALTOGETHER.

BUT EVERYONE DESERVES TO HAVE FUN IN THE SUN. JOINING US NOW IS HEALTH CARE PROVIDER, MELINDA GREENFIELD, WITH HOW MODERATE-TO-SEVERE PLAQUE PSORIASIS PATIENTS CAN MAKE THE MOST OF WARM WEATHER.

BIO-Dr. Melinda Greenfield Bio

Dr. Melinda Greenfield is a Board Certified Dermatologist in private practice since 1999. She has offices in Ponte Vedra Beach, FL and Albany, GA and has an online Telehealth practice in nine states.

Dr. Greenfield attended The University of Maryland for her undergraduate degree and Nova Southeastern University for Medical School. She completed her internship at Sinai Hospital of Baltimore and her Dermatology residency at St. Barnabas Hospital in the Bronx, NY.

Dr. Greenfield is past president of the Dougherty County Medical Society, the Georgia Osteopathic Medical society and previously served on the Editorial Board of the Journal of the American Osteopathic College of Dermatology.

Dr. Greenfield is a clinical assistant professor at The Georgia Campus of the Philadelphia College of Osteopathic Medicine, The Medical College of Georgia, PCOM South Georgia and The Orlando College of Osteopathic Medicine. She teaches the second-year dermatology curriculum to medical students and has students and residents rotate in her office throughout the year.

Dr. Greenfield has lectured at multiple meetings throughout the years and has authored four publications. She participated in an episode of The Balancing Act on Lifetime TV that highlighted psoriasis and is on the Speaker Board for several pharmaceutical companies.

In her free time, Dr. Greenfield enjoys bike riding, working out in the gym, gardening, cooking and spending time with her family.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ILUMYA^® (tildrakizumab-asmn)?

Do not use ILUMYA if you have had a severe allergic reaction to ILUMYA or any of its ingredients.

Get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

• feel faint
• trouble breathing or throat tightness
• swelling of your face, eyelids, lips, mouth, tongue or throat
• chest tightness
• skin rash

What is ILUMYA?

ILUMYA is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).

IMPORTANT SAFETY INFORMATION (continued)

ILUMYA is a medicine that may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with ILUMYA and may treat you for TB before you begin treatment with ILUMYA if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ILUMYA.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

• fever, sweats, or chills
• muscle aches
• weight loss
• cough
• warm, red, or painful skin or sores on your body different from your psoriasis
• diarrhea or stomach pain
• shortness of breath
• burning when you urinate or urinating more often than normal
• blood in your phlegm (mucus)

Before receiving ILUMYA, tell your healthcare provider about all of your medical conditions, including if you:

• have any of the conditions or symptoms listed in the section “What is the most important information I should know about ILUMYA?”
• have an infection that does not go away or that keeps coming back
• have TB or have been in close contact with someone with TB
• recently received or are scheduled to receive a vaccine (immunization). You should avoid receiving live vaccines during treatment with ILUMYA.
• are pregnant or plan to become pregnant. It is not known if ILUMYA can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if ILUMYA passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

It is not known if ILUMYA is safe and effective in children under 18 years of age.

What are the possible side effects of ILUMYA?

ILUMYA may cause serious side effects. See “What is the most important information I should know about ILUMYA?”

The most common side effects of ILUMYA include: upper respiratory infections, injection site reactions and diarrhea. These are not all of the possible side effects of ILUMYA. Call your doctor for medical advice about side effects.

You are encouraged to report any negative side effects of ILUMYA to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You are also encouraged to report side effects or ADEs (adverse drug events) to our Drug Safety Department at 1-800-406-7984 or drug.safetyUSA@sunpharma.com (preferred) with as much information as available.

Please read the full Prescribing Information and Medication Guide for ILUMYA and discuss any questions with your doctor.

#warmerweather #psoriasis #tips #skin #plaque #symptoms #sunlight #embarrassed #drmelindagreenfield #patients #healthcare #medical #sinaihospital #ilumya #tildrakizumab-asmn

The post IT’S MORE THAN SKIN DEEP How Warmer Weather Affects Psoriasis & Tips to Help Those Impacted appeared first on Good News!.

Approximately 1 in 5 people living with cancer in the United States are diagnosed with a rare cancer; however, these are often misunderstood and overlooked. Cholangiocarcinoma, or CCA, is a rare cancer affecting fewer than 10,000 people in the U.S. CCA arises from the cells within the bile ducts, a series of thin tubes that reach from the liver to the small intestine. Because of its nonspecific symptoms, patients with CCA are often diagnosed at a late or advanced stage when the prognosis is poor and survival rates are low.

www.testmycholangio.com

Innovative technology called biomarker testing has made it possible to look very closely inside each person’s tumors to identify genomic changes. Determining the genomic makeup of a person’s tumor can help doctors understand more about the tumor.

National Cancer Survivors Day serves as an opportunity to rally around those living with CCA and other rare cancers, recognizing the challenges they face, and providing the community with the national attention they need and deserve. Dr. Rachna Shroff discusses CCA, along with importance of biomarker testing. Dr. Shroff is joined by Melinda Bachini, Director of Advocacy for the Cholangiocarcinoma Foundation and a CCA survivor, who will share her personal symptom and diagnosis journey.

Interview is courtesy of Incyte Corporation

Rachna T. Shroff, MD, MS, is an Associate Professor of Medicine and Chief of GI Medical Oncology as well as Leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center (UACC). She is the Director of UACC’s Clinical Trials Office as well as the Director of the Arizona Clinical Trials Network (ACTN). More recently, she was appointed as the Associate Dean for Clinical and Translational Research for UA College of Medicine-Tucson. She came to UACC from MD Anderson Cancer Center in Houston, TX where she was on faculty from 2010-2018 after completing her medical oncology fellowship there.

Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and biliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary subcommittee Co-Chair for the Southwest Oncology Group (SWOG) and as a Program Committee member for GI ASCO. She also is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the national PI for SWOG 1815 which is investigating a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase 2 study she led that is now published in JAMA Oncology. Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and has numerous peer-reviewed publications in this area.

BIO
Melinda Bachini is an 11-year survivor of cholangiocarcinoma. In 2012 she was treated at the National Cancer Institute by Dr. Rosenberg with a clinical trial using Adoptive Cell Therapy with TIL. Due to her exceptional and breakthrough response to NIH treatment, her story was published in the New York Times and other media.

Melinda is married and the mother of six children, grandmother to one. She is passionate about patient advocacy. Her personal experience with previous and current treatments allows for great insight into patients participating in clinical trials. Her position as Director of Advocacy for the Cholangiocarcinoma Foundation allows Melinda to interact, support and educates others touched by this cancer. She shares her story with as many cancer patients as possible in hopes of giving courage to those in need.

Melinda had previously volunteered for seven years with the Cholangiocarcinoma Foundation and in August of 2017 came on as staff. She also worked for over 15 years in the Emergency Medical Field as an EMT Paramedic.

Melinda serves as a patient advocate for the NCI Hepatobiliary Task Force, the NCI Patient Advocate Steering Committee (PASC), ECOG-ACRIN GI Committee, ECOG-ACRIN Cancer Research Advocacy Committee, NCI Council of Research Advocates, and the NCCN Hepatobiliary Guideline Panel. Melinda attended 2016, 2017, and 2018 NCCS, CPAT Symposium, and advocated on Capitol Hill. She participated as a panelist in the Cancer Moonshot – Community Oncology Event at the White House, told her personal story, and was introduced by her state Senator for the Innovation and Access in Quality Cancer Care at the US Capitol. In June of 2017 she spoke with nine US Senators at NIH to share her personal story of how research has prolonged her life. Melinda has served as a Consumer Reviewer for the Department of Defense for several years.

#cancer #survivor #cholangiocarcinoma #navigating #diagnosis #rachna #shroff #melinda #bachini #incyte #cca #medical #educate #support #emergency #liver #pancreatic #biliary #hepatobiliary #oncology

The post National Cancer Survivors Day is June 6, We discuss Cholangiocarcinoma appeared first on Good News!.